[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arrhythmia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arrhythmia":652},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,49,86,115,142,171,193,215,239,258,288,318,343,372,396,417,442,459,484,509,529,553,581,608,632],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100644842",false,"NCT07675434","Prospective Cohort of Acute Cardiology Referrals in an Ambulatory Day-Hospital Setting","CESAR Study: Prospective Cohort of Consecutive Patients Undergoing Cardiologic Evaluation in a Specialized Ambulatory Referral Unit","CESAR","Inclusion Criteria:\n\n\\- The study will include all consecutive patients referred to ambulatory day-hospital unit for suspicion of acute or sub-acute cardiovascular disease at the Cardiology Department of Lariboisière University Hospital.\n\nExclusion Criteria:\n\n* Patient unable to provide informed consent\n* Patient not affiliated to French social security","ALL","18 Years",{"count":20,"type":21},25000,"ESTIMATED","10 Years","OBSERVATIONAL","Suspected acute or subacute cardiovascular diseases-including chest pain, dyspnea, and palpitations-are among the most common reasons for unscheduled emergency department visits and pre-hospital referrals. Despite this high clinical burden, the diagnostic yield is often limited, with a frequent mismatch between initial clinical suspicion and final diagnosis, contributing to substantial healthcare utilization and hospitalization rates. Current evidence is largely focused on specific conditions such as acute coronary syndromes, heart failure, arrhythmias, or pulmonary embolism, and rarely integrates the full spectrum of clinical, biological, and imaging data obtained during initial evaluation.\n\nTo address this gap, we will establish a prospective cohort of all consecutive patients referred to the ambulatory day-hospital cardiology unit at Lariboisière University Hospital. This unit acts as a specialized downstream referral structure within the emergency care pathway, receiving patients after triage by emergency physicians, pre-hospital regulation services (SAMU), mobile intensive care units (SMUR), or emergency departments. Although it does not capture all suspected cardiovascular emergencies, it represents a selected real-world population deemed to require specialized acute cardiology assessment.\n\nThe primary objective is to assess the frequency of cardiac conditions diagnosed in this cohort. Secondary objectives include characterization of patient profiles and diagnostic pathways; evaluation of the diagnostic and prognostic performance of clinical, biological, imaging, and multimodal parameters using final Heart Team diagnosis as reference; analysis of prior health history and healthcare utilization; and assessment of the medico-economic burden of suspected acute cardiovascular disease. The study will further support the development of a dedicated biobank and the validation of next-generation biomarkers, including AI-driven and voice-based markers, as well as decision-support algorithms for binary classification of cardiac involvement. Through integration of multimodal data and linkage with national health records, this approach aims to improve diagnostic accuracy, risk stratification, and understanding of the healthcare impact of acute cardiovascular presentations in a real-world setting.",[26,27,28,29,30],"Acute Coronary Syndromes","Heart Failure","Pulmonary Embolism, Deep Vein Thrombosis","HTN-Hypertension","Arrhythmia",[32,33,34,35,36],"Cardiovascular emergencies","Multimodality Imaging","Acute care","Prospective cohort","Biomarkers","NOT_YET_RECRUITING","2026-06-26",{"date":40,"type":41},"2026-06-30","ACTUAL",{"date":43,"type":21},"2026-08-01",{"date":45,"type":21},"2041-08-01",{"name":47,"class":48},"Assistance Publique - Hôpitaux de Paris","OTHER",{"id":50,"slug":4,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100627110","NCT07444372","Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation","Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation: A Multicenter, Open-label, Randomized Clinical Trial","STOP-AFib","Inclusion Criteria:\n\nPatients must meet all of the following conditions to be eligible for the study:\n\n* Age 18-75 years.\n* Patients with persistent AF scheduled for first-time catheter ablation.\n* Diagnosed with OSA.\n* Able to tolerate CPAP therapy.\n* Capable of understanding and complying with the study protocol.\n* Willing to sign the informed consent form.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded from the study:\n\n* Secondary AF.\n* Left atrial anteroposterior diameter 60mm (measured via parasternal long-axis view).\n* Left ventricular ejection fraction \\\u003C 30%.\n* Comorbid moderate-to-severe mitral stenosis or history of prosthetic valve replacement (mechanical or bioprosthetic).\n* Pregnant or breastfeeding women.\n* History of myocardial infarction, percutaneous coronary intervention, or cardiac surgery within 3 months prior to screening.\n* History of stroke or transient ischemic attack within 6 months prior to screening.\n* Perioperative complications related to the ablation procedure occurring prior to randomization.\n* Inability to discontinue antiarrhythmic drugs (AADs) post-procedure due to other reasons.\n* Life expectancy \\\u003C 1 year.\n* Central sleep apnea.\n* Conditions requiring ventilatory support, including obesity hypoventilation syndrome (defined as BMI \\> 30kg\u002Fm² and awake PaCO₂ \\> 45mmHg), amyotrophic lateral sclerosis, or chronic obstructive pulmonary disease with \\> 1 episode of respiratory failure or hypercapnia.\n* Treatment-emergent central sleep apnea during CPAP tolerance assessment that cannot be corrected prior to randomization.\n* Receipt of instrumental or surgical treatment for OSA within 3 months prior to screening, including CPAP, oral appliances, ENT surgery, or bariatric surgery.\n* Use of glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide receptor agonists, or glucagon receptor agonists for weight loss within 3 months prior to screening, or plans to initiate such medications within the next year.\n* Current participation in other drug or device trials.","75 Years",{"count":58,"type":21},658,"INTERVENTIONAL",[61],"NA","Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.\n\nThis study aims to evaluate the clinical benefit of post-ablation CPAP therapy in AF patients with comorbid OSA.\n\nParticipants will:\n\n* Be randomly assigned to either the CPAP group or the usual care group.\n* If in the CPAP group, use a CPAP device for 12 months.\n* Wear an ambulatory ECG recorder for a 7-day period at 3, 6, 9, and 12 months post-operation.\n* Complete follow-up checkups either at the clinic or over the phone at 1, 3, 6, and 12 months after their procedure.",[64,65,66,67,30,68],"Obstructive Sleep Apnea","Sleep Disorder (Disorder)","Atrial Fibrillation (AF)","Sleep Disordered Breathing (SDB)","Continuous Positive Airway Pressure",[64,68,70,71,72,73,74],"Atrial Fibrillation","Ablation of atrial fibrillation","Sleep Disordered Breathing","Clinical Trial","Catheter Ablation","RECRUITING","2026-06-14",{"date":78,"type":41},"2026-06-16",{"date":80,"type":41},"2026-05-12",{"date":82,"type":21},"2029-01-31",{"name":84,"class":48},"Beijing Anzhen Hospital",27,{"id":87,"slug":4,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100642535","NCT07644715","AI-powered ECG Analysis for Deadly Arrhythmias and ICI Myocarditis","Efficient Deep Learning Approaches for the Rapid and Interpretable Detection of Deadly Arrhythmias in ECG Data","ELDORA","Inclusion Criteria:\n\n* subjects included in participating existing or ongoing ECG cohorts made available to ECGInsight\n* availability of ECG data (digital waveform or scanned\u002Fpaper ECG suitable for digitization) and relevant clinical\u002Fdemographic metadata\n* data use permitted by applicable ethical, regulatory, contractual and GDPR requirements.\n\nExclusion Criteria:\n\n* datasets or individual records for which required approvals, data-sharing agreements, de-identification\u002Fanonymization, or minimum ECG\u002Fmetadata quality requirements are not met. No interventional study treatment is assigned.",true,{"count":95,"type":21},127000,"ELDORA is a non-interventional observational data-science study aiming to develop and validate clinical-grade artificial intelligence tools applied to electrocardiogram (ECG) data. The project will standardize heterogeneous ECGs, create the ECGInsight harmonized database, and train interpretable models for life-threatening arrhythmia risk prediction, especially Torsades-de-Pointes\u002Flong QT syndrome and immune checkpoint inhibitor (ICI)-induced myocarditis. The project uses existing and ongoing national and international ECG cohorts with de-identified clinical metadata; AI outputs are intended for research\u002Fmodel development and are not used to drive patient care during the study.",[30,98,99],"Long QT Syndrome","Immune Checkpoint Inhibitor-Related Myocarditis",[101,102,103,104],"ECG","AI","Immune Checkpoint Inhibitors-Related Myocarditis","long QT","2026-06-08",{"date":107,"type":41},"2026-06-12",{"date":109,"type":41},"2026-01-01",{"date":111,"type":21},"2029-12-31",{"name":113,"class":48},"Groupe Hospitalier Pitie-Salpetriere",1,{"id":116,"slug":4,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100578200","NCT06808204","Quality of Life Before and After Transcatheter Ablation in Children With Arrythmias","QUALICATRYTHM","Inclusion Criteria:\n\n* Patients aged 5 to 17\n* Patients with a rhythm disorder,\n* Patients with indication for catheter ablation according to PACES (Pediatric and Congenital Electrophysiology Society) recommendations,\n* Patients and\u002For their parents\u002Flegal guardians who have given their non-objection to the study.\n\nExclusion Criteria:\n\n* Refusal of child or parents\u002Flegal guardians\n* Unability to understand and\u002For fill the quality of life questionnaire","5 Years","17 Years",{"count":124,"type":21},200,"The goal of this clinical trial is to evaluate the improvement in the quality of life after the transcatheter ablation in children from 5 to 17 years old suffering for arrythmia who need a transcatheter ablation (according to PACES recommendations). The main question is how to evaluate an improvement in the quality of life in these children, according to different questionnaires?\n\nParticipants will answer some questionnaires to get a global evaluation of the quality of life:\n\n* Peds QL 4.0\n* Peds QL 4.0 by proxy, which will be completed by the parents\n* Ricci and Gagnon questionnaire\n* Child Depression Index\n* State and Trait Anxiety Inventory",[30],[128,129,130,131],"children","arrythmia","transcatheter ablation","quality of life","2026-05-15",{"date":134,"type":41},"2026-05-19",{"date":136,"type":41},"2025-09-23",{"date":138,"type":21},"2027-03-23",{"name":140,"class":48},"Hospices Civils de Lyon",7,{"id":143,"slug":4,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":151,"conditions":152,"keywords":155,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":170},"100078039","NCT00271180","Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products","Medtronic CRDM Product Performance Report","PPR","Subjects who meet the following inclusion criteria and do not meet any of the following exclusion criteria are eligible for enrollment.\n\nInclusion Criteria:\n\n• Subject or appropriate legal guardians provide written informed consent and\u002For authorization for access to and use of health information as required by an institution's IRB\u002FMEC\u002FREB\n\nAND one of the following must also apply:\n\n* Subject is indicated for implant or within 30 days post-implant of at least one Medtronic market-released product used for a pacing, sensing or defibrillation application\n* Subjects who participated in a qualifying study (IDE) of a Medtronic market-released product with complete implant and follow-up data and subject or appropriate legal guardian authorizes release of subject study data\n\nExclusion Criteria:\n\n* Subjects who are, or will be inaccessible for follow-up\n* Subjects with exclusion criteria required by local law (EMEA only)\n* Subjects receiving an implant of a Medtronic device at a non-participating center and the implant data and current status cannot be confirmed within 30 days after implant\n* Subjects implanted with a Medtronic device whose predetermined enrollment limit for that specific product has been exceeded",{"count":150,"type":21},20000,"The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.",[30,153,27,154],"Bradycardia","Sinus Tachycardia",[156,157,158,159],"Cardiac Pacing","Implantable Cardioverter Defibrillator","pacemaker","Sinus Bradycardia","2026-05-05",{"date":162,"type":41},"2026-05-07",{"date":164,"type":41},"1983-01",{"date":166,"type":21},"2040-12",{"name":168,"class":169},"Medtronic","INDUSTRY",320,{"id":172,"slug":4,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":93,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":179,"studyType":23,"phases":4,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":114},"100631485","NCT07501299","HeartBeam ECG Registry","Collection of ECG Recordings Using the HeartBeam 3-Lead ECG Recorder","Inclusion Criteria:\n\nUndergoing ECG as part of standard of care Able and willing to provide written informed consent\n\nExclusion Criteria:\n\nOpen chest wounds or surgery to the chest or abdomen within 30 days Inability to complete ECG acquisition with either HeartBeam device or standard 12-L ECG Unstable condition where registry participation may interfere with care",{"count":178,"type":21},600,"1 Day","The HeartBeam ECG Registry will collect ECG recordings acquired with the HeartBeam System with relevant clinical information in clinical settings.",[70,182,153,183,30],"Atrial Flutter","Tachycardia","2026-03-24",{"date":186,"type":41},"2026-03-30",{"date":188,"type":21},"2026-03",{"date":190,"type":21},"2028-12",{"name":192,"class":169},"HeartBeam, Inc.",{"id":194,"slug":4,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":4},"100630712","NCT07491237","RHYthm and Myocardial Function Relationship Evaluation in Heart Diseases","RHYME-HD","Inclusion Criteria:\n\n* Only patients aged \\> 18 years with a history of arrhythmia warranting non-pharmacological treatment according to the guidelines will be selected.\n* Collection of informed consent for the prospective cohort.\n* For the retrospective cohort, the Promoter has carried out a Data Protection Impact Assessment (DPIA), which ascertained the adequacy of the technical and organisational measures adopted to ensure the protection of the fundamental rights and freedoms of data subjects, in accordance with Article 89 of Regulation (EU) 2016\u002F679 and the guidelines of the Data Protection Authority. Data processing will be limited to the purposes of the study and conducted in accordance with the principles of minimisation, pseudonymisation and security, in compliance with the guarantees defined by the Data Protection Authority.\n\nExclusion Criteria:\n\n* Patients who, upon initial assessment at our centre, do not present arrhythmias that would indicate non-pharmacological treatment.\n* Patients for whom it is not possible to obtain adequate medical history and\u002For follow-up through medical examination or telephone consultation.\n* Refusal to give informed consent to participate in the study.",{"count":200,"type":21},253,"Arrhythmias are widespread among the global population. Although they can occur in healthy hearts, they are often the manifestation of a hereditary or acquired heart muscle disease, and may be the cause or, more often than not, the consequence.\n\nIn recent decades, with advances in medical knowledge and technology, non-pharmacological therapies for arrhythmias have become increasingly popular. These fall into two broad categories: therapies aimed at electrostimulation and those aimed at ablation of arrhythmias.\n\nThe selection of patients eligible for these procedures is essential for the effectiveness of the therapy, the reduction of complications and the optimisation of resources.\n\nNot all patients, even those selected according to guidelines, respond equally to the chosen therapy. Other patients, due to their clinical\u002FECG characteristics, do not have clear indications and remain in a borderline area where the class of evidence and\u002For recommendation of the guidelines is less stringent. Still others develop recurrences or complications during follow-up that require further intervention.\n\nIn this context, it is essential in the study of these patients not only to use standard instrumental examinations, such as echocardiograms, Holter ECGs and stress tests (simple and cardiopulmonary), but also and above all to use advanced imaging methods (STE, 3D echo, MRI, CT, PET-CT) and remote monitoring tools that integrate diagnostic algorithms managed by artificial intelligence.\n\nIn light of these considerations, our project consists of conducting an observational study that includes all patients with arrhythmias who are candidates for electrostimulation and\u002For ablation procedures at the Arrhythmology Unit and\u002For followed up at the Arrhythmology Clinic of our Polyclinic, in order to assess the clinical and\u002For imaging characteristics associated with a worse prognosis in this population, in terms of response to therapy and development of complications. Our main aim is to identify, within the above-mentioned population, the subgroups of responder patients versus non-responder patients, i.e. those with a worse prognosis , who deserve greater attention and more frequent follow-up.",[30,203,204,70,205,27,206],"Cardiomyopathy, Dilated","Systolic Dysfunction","Ventricular Arrythmia","Cardiomyopathies","2026-03-18",{"date":184,"type":41},{"date":210,"type":21},"2026-04-15",{"date":212,"type":21},"2031-12-31",{"name":214,"class":48},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":216,"slug":4,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":238,"locationsCount":114},"100623319","NCT07395089","Computed Tomography of Pulse-Field Ablation","Atrial Remodeling Associated With Pulse-Field Ablation of Atrial Fibrillation: a Computed Tomography Study","CT-PFA","Inclusion Criteria:\n\n1. Age≥18 years at the time of AF ablation\n2. AF ablation by pulse-field ablation (BOSTON SCIENTIFIC FARAPULSE) or by radiofrequency (any manufacturer) between 2020 and 2024\n3. Paroxysmal or non-paroxysmal AF\n4. Pre-ablation CT data available and of high quality\n5. Post-ablation CT data available and of high quality\n6. Post-ablation CT performed 3-months (+- 2 weeks) after AF ablation\n\nExclusion Criteria:\n\n1. Low quality CT, non-homogeneous contrast agent perfusion\n2. Post-ablation CT performed in another center\n3. Patients in which pre- and post-ablation CTs do not share common phases\n4. Patients who underwent ethanol infusion in the vein of Marshall",{"count":124,"type":21},"Radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF) reduces left atrial (LA) volume post-ablation, a phenomenon termed reverse atrial remodeling, indicative of successful reversal of atrial cardiomyopathy progression. In contrast, pulse field ablation (PFA), a novel non-thermal technology, offers a promising efficacy and safety profile without inducing persistent atrial fibrosis. While RFCA-associated reverse atrial remodeling is well-documented, it remains uncertain whether PFA, operating on a non-thermal paradigm, also promotes this remodeling, which would enhance its physiological relevance in AF treatment. Additionally, RFCA studies show that LA wall thickness at the pulmonary vein (PV) antrum can predict PV reconnection and arrhythmia recurrence, but whether PFA affects LA thinning or enables similar predictions from post-treatment computed tomography (CT) scans is unknown. Moreover, epicardial adipose tissue (EAT), strongly linked to LA abnormalities and AF recurrence, can be quantified via CT, yet the impact of PFA on LA EAT remains unexplored. Finally, PFA's versatility, particularly in isolating the LA posterior wall (LAPW) in non-paroxysmal AF, raises questions about its effect on posterior wall thinning or EAT changes, factors associated with post-ablation recurrence",[66,30],[226,227,228,229,230,231],"Ablation","Reverse Atrial Remodeling","Radiofrequency Catheter Ablation","Pulse Field Ablation","Pulmonary Vein Reconnexion","Epicardial Adipose Tissue","2026-02-03",{"date":234,"type":41},"2026-02-09",{"date":236,"type":21},"2026-02",{"date":236,"type":21},{"name":47,"class":48},{"id":240,"slug":4,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":4},"100622923","NCT07389928","Comprehensive Biomarker ProfiliNg in PatieNts With VEntriCular TachyCardia, PremAtuRe VEntricular Contractions, and AVNRT","Comprehensive Biomarker ProfiliNg in PatieNts With VEntriCular TachyCardia, PremAtuRe VEntricular Contractions, and AVNRT (CONNECT-CARE)","CONNECT-CARE","Inclusion criteria:\n\n* Age ≥ 18 years\n* Catheter ablation due to VT, PVC, or AVNRT\n* Written informed consent\n\nExclusion criteria:\n\n* Infection or inflammatory disease at time of sampling\n* Pregnancy\n* Inability to comply with study procedures\n* Life expectancy \\\u003C 1 year not due to arrhythmia",{"count":124,"type":21},"To systematically evaluate multiple biomarkers in patients ventricular tachycardia (VT), premature ventricular contractions (PVC), atrioventricular nodal reentrant tachycardia (AVNRT) undergoing catheter ablation to elucidate their mechanistic relevance and predictive value.",[30],"2026-01-28",{"date":251,"type":41},"2026-02-05",{"date":253,"type":21},"2026-04",{"date":255,"type":21},"2030-10",{"name":257,"class":48},"University of Luebeck",{"id":259,"slug":4,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":59,"phases":266,"briefSummary":269,"conditions":270,"keywords":275,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":4},"100620611","NCT07359872","Relaxin Therapy for Atrial Fibrillation","Relax-in-AF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosed with AF and scheduled for elective catheter ablation for AF\n\nExclusion Criteria:\n\n* Enrollment in another Greater than Minimal Risk Study\n* Pregnant, nursing, or sexually active females not using birth control or having been surgically sterilized\n* Females who plan to become pregnant during the trial period\n* Patients diagnosed with \"permanent\" AF, complete heart block, or a reversible cause of AF (e.g., transient thyrotoxicosis)\n* Patients that require antiarrhythmic medication to started or continued during and after the ablation procedure.\n* Patients unable to tolerate Relaxin therapy or unable or unwilling to provide informed consent",{"count":265,"type":21},208,[267,268],"PHASE1","PHASE2","Atrial fibrillation (AF) is the most common heart rhythm disorder. The presence of AF increases the risk of death and is associated with a 5-6-fold increase in stroke incidence, due almost exclusively to thrombus formation in the heart. Current therapies for AF are limited. The evaluation of new, more effective treatments for preventing AF recurrence remains a critical unmet clinical need. AF is considered a progressive disease that increases in prevalence with age and can convert from \"paroxysmal\" to \"persistent\" to \"permanent\" AF in a single individual. This progression results, in part, from high oxidative stress and progressive adverse electrical changes in the heart. Compelling preclinical and clinical data indicate that Relaxin, a naturally occurring peptide hormone, may reverse the electrical remodeling. Thus, our overall objective is to investigate the effects of Relaxin in Veterans who have failed medical management for symptomatic AF and is referred to Cardiac Electrophysiology Laboratory for catheter ablation and pulmonary vein isolation. We will determine whether Relaxin therapy, in addition to the standard of care, counteracts the oxidative stress-related electrical derangement and reduces the post-ablation AF burden. A unique aspect of this proposal is that it is based in part on observations derived from the basic, translational and computational labs of the PI and co-investigators and from the observations by the PI while caring for patients with AF. As such, this proposal represents a true progression from the bench to the bedside. If successful, our findings may lead to the design of a new, more effective treatment for a major unmet public health problem in the United States as well as the world.",[66,30,271,272,273,27,74,274],"Oxidative Stress","Stroke","Major Cardiovascular Event","Ablation of Atrial Fibrillation",[276,277],"randomized controlled crossover trial","Randomized clinical trial","2026-01-21",{"date":280,"type":41},"2026-01-22",{"date":282,"type":21},"2027-01-01",{"date":284,"type":21},"2030-12-31",{"name":286,"class":287},"Deeptankar DeMazumder","FED",{"id":289,"slug":4,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":298,"conditions":299,"keywords":302,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":317},"100112813","NCT00733590","Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention","Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention (PROSe-ICD)","PROSe-ICD","Inclusion Criteria:\n\n* History of acute MI at least 4 weeks old\n* Non-ischemic LV dysfunction for at least 9 months\n* Who have an ejection fraction (EF) \\\u003C or = to 35%\n* Undergone elective replacement indicator (ERI) generator replacement of an FDA-approved ICD for primary prevention of SCD within 24 months of enrollment.\n* Who have primary prevention implants.\n\nExclusion Criteria:\n\n* ICD generator replacement for secondary prevention\n* Inability or unwillingness to provide valid informed consent\n* New York Heart Association Class IV heart failure\n* Patients with pre-existing Class 1 indications for pacemaker therapy.","85 Years",{"count":297,"type":21},1500,"The overall hypothesis of this study is that subtle interactions between structural (substrate) and functional (trigger) abnormalities of the heart, some of which are genetically-determined, can be used to identify patients at high risk of sudden cardiac death (SCD). Such information may be used to better define patients most likely to benefit from replacement of an internal defibrillator (ICD). The prospective, observational study to enroll, categorize and follow patients who receive an ICD pulse generator replacement for primary prevention of SCD (PROSe-ICD) was established to :\n\n1. to gain a better understanding of the biological mechanisms that predispose to SCD\n2. to develop readily determined clinical, electrocardiographic, genetic and blood protein markers identify patients with an increased risk of dying suddenly",[300,301,30,206],"Heart Failure, Congestive","Death, Sudden, Cardiac",[303,304,305,306,307],"defibrillator, implanted","genomics","electrocardiography","electrophysiological study","proteomics","2026-01-15",{"date":310,"type":41},"2026-01-20",{"date":312,"type":41},"2003-06",{"date":314,"type":21},"2029-03",{"name":316,"class":48},"Johns Hopkins University",4,{"id":319,"slug":4,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":17,"minAge":324,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":59,"phases":327,"briefSummary":328,"conditions":329,"keywords":330,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":342},"100535352","NCT06250712","Hativ® ELectrocardiogram Monitoring on Patients With Suspected Arrhythmia","HELP-A","Inclusion Criteria:\n\n* Patients who have arrhythmia symptoms but are not diagnosed on a 12-lead electrocardiogram and require additional tests.\n* Patients who can use a smartphone\n\nExclusion Criteria:\n\n* Patients who have cardiac implantable electronic devices(CIEDs)\n* Patients who can't use handheld ECG","19 Years",{"count":326,"type":21},588,[61],"HELP-A study is a single-center, randomized, controlled trial. A total of 588 patients enrolled during the 2 years of enrollment period and followed for 1 month of follow-up period. This study aims to compare diagnostic yield between continuous ECG Patch and intermittent handheld ECG in patients with arrhythmia symptoms.",[30],[331,332,30],"Palpitation","Dizziness","2025-09-22",{"date":335,"type":41},"2025-09-26",{"date":337,"type":41},"2024-02-22",{"date":339,"type":21},"2025-12-31",{"name":341,"class":48},"Wonju Severance Christian Hospital",3,{"id":344,"slug":4,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":349,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":351,"conditions":352,"keywords":360,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":114},"100600398","NCT07096973","Cardiac REhabilitation COhort at the Medicine Campus DaVos to invEstigate Recovery","RECOVER","Inclusion Criteria:\n\n* Patients undergoing CR at the HGK\n* Written informed consent\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language to understand study documents, the interview, or questionnaires interview without translation\n* Physical or psychological incapability to participate in the study",{"count":350,"type":21},10000,"The RECOVER study, titled Cardiac Rehabilitation Cohort at the Medicine Campus Davos for Exploration of Recovery, is a prospective, non-interventional, monocentric cohort study conducted at the Hochgebirgsklinik Davos. The study is sponsored by Medicine Campus Davos AG and the Kühne Foundation, with an estimated start date in July 2025 and planned completion by December 2034, with the possibility of extension.\n\nThe principal investigator of the study is PD Dr. David Niederseer from Hochgebirgsklinik Davos, who also represents the study. The research team includes co-investigators such as Prof. Dr. Stefan Blankenberg and Prof. Dr. Andreas Ziegler from Cardio-CARE, Medicine Campus Davos, as well as Dr. Jan Vontobel from Hochgebirgsklinik Davos.\n\nThe study will enroll patients referred to Hochgebirgsklinik Davos for cardiac rehabilitation who provide informed consent. Cardiac rehabilitation is an evidence-based therapy for patients with heart disease, including those who have undergone cardiac procedures or surgeries.\n\nThe primary objectives are to evaluate baseline patient characteristics, rehabilitation strategies, predictors of recovery, and clinical outcomes during and after rehabilitation. To support this, a detailed database and biobank will be established to allow for comprehensive phenotyping, extensive clinical assessments, and long-term follow-up.\n\nRECOVER seeks to gain translational insights into how patient-specific factors - such as genetics, plasma, digital and clinical biomarkers, and comorbidities - influence long-term clinical outcomes. The goal is to identify modifiable risk factors to optimize individualized therapeutic approaches in cardiac rehabilitation.",[353,27,354,355,356,357,358,359,30],"Cardiac Rehabilitation","Cardiac Arrest (CA)","ACS (Acute Coronary Syndrome)","CABG","Valve Anomalies","LVAD (Left Ventricular Assist Device)","Heart Transplantation",[361,362],"cardiovascular diseases","cardiac rehabilitation","2025-09-11",{"date":365,"type":41},"2025-09-17",{"date":367,"type":41},"2025-08-05",{"date":369,"type":21},"2040-08-05",{"name":371,"class":48},"Hochgebirgsklinik Davos",{"id":373,"slug":4,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":59,"phases":380,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":395},"100592142","NCT06989580","BIO|CONCEPT.BIOMONITOR-HF Collect Clinical Data From Heart Failure Patients Using BIOMONITOR Devices With a Study Specific Research Software","Clinical Data Collection to Develop Improved Arrhythmia and Heart Failure Management Using BIOMONITOR","Inclusion Criteria:\n\n* Patient has diagnosed heart failure for ≥90 days and current symptoms compatible with NYHA class II-III (according to most recent assessment)\n* At least ONE of the following:\n\nAt least one documented admission with a primary diagnosis of worsening heart failure within last 12 months prior to enrollment;\n\nOR Unscheduled outpatient visit with increase of oral loop diuretics (more than 2-fold) or IV diuretic or ultrafiltration therapy for acute WHF within last 6 months prior to enrollment;\n\nOR elevated NT-proBNP\u002FBNP values within last 3 months prior to enrollment i.e.:\n\nIf LVEF \\>50% --\\> Patients in SR: \\>450 \u002F \\>150 pg\u002Fml; Patients with AF present: \\>900 \u002F \\>300 pg\u002Fml\n\nIf LVEF \\\u003C50% --\\> Patients in SR: \\>900 \u002F \\>300 pg\u002Fml; Patients with AF present: \\>1800 \u002F \\>450 pg\u002Fml\n\n* Ability to understand the nature of the study\n* Willingness to provide written informed consent\n* Ability and willingness to perform follow-up visits at the study site and via phone\n* Ability and willingness to use the CardioMessenger and acceptance of the BIOTRONIK Home Monitoring concept\n\nExclusion Criteria:\n\n* Implanted with pacemaker, ICD or CRT device or ICM\n* Class I indication for a pacemaker, ICD or CRT according to current guidelines.\n* Permanent or long-standing persistent AF\n* Stroke, MI or PCI\u002FCABG within 3 months prior to enrollment\n* Patient is on chronic renal or peritoneal dialysis\n* Patient has complex adult congenital heart disease\n* Patient has active cancer involving chemotherapy, immunotherapy or radiation therapy\n* Patient life expectancy is less than 1 year\n* Age \\\u003C18 years\n* Patient is participating in any other device or drug trial that may interfere with the treatment or protocol of this study or may significantly affect the study outcomes",{"count":379,"type":21},300,[61],"\\[Plain language\\]: Heart failure (HF) patients often experience irregular heartbeats, known as arrhythmias. Atrial fibrillation (AF) is common among HF patients and can worsen their condition, leading to strokes and higher death rates. Most of what we know about arrhythmias in HF comes from patients with devices like ICDs or CRTs, which help manage heart rhythms. However, this study focuses on HF patients who don't qualify for these devices.\n\nResearchers use the BIOMONITOR IV, a device that tracks heart activity remotely over a long period. The goal is to understand how often arrhythmias occur in these patients and to develop a predictive algorithm for worsening HF (WHF). This algorithm could help doctors intervene early and improve treatment, reducing hospital visits and deaths related to WHF.\n\nTo make the BIOMONITOR IV more effective for HF management, its firmware is updated to collect additional data, such as fluid levels, breathing rate, and body position. These factors may be important for predicting WHF events.",[27,30,383,70],"Decompensated Heart Failure",[385],"Worsening Heart Failure (WHF)","2025-09-05",{"date":388,"type":41},"2025-09-08",{"date":390,"type":41},"2025-08-22",{"date":392,"type":21},"2028-12-31",{"name":394,"class":169},"Biotronik SE & Co. KG",2,{"id":397,"slug":4,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":404,"conditions":405,"keywords":408,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":114},"100068127","NCT00138931","Genetics of Cardiovascular and Neuromuscular Disease","Genetic Studies of Patients and Their Families With Inherited Cardiovascular and Neuromuscular Diseases.","Inclusion Criteria:\n\n* Patients of all ages will be considered for the study. In particular, families with more than one affected relative will be sought.\n\nExclusion Criteria:\n\n* Subjects without a suspected inherited cardiovascular or neuromuscular disorder will be excluded from this study.",{"count":403,"type":21},2000,"We are studying the genetics of human cardiovascular and neuromuscular disease. There are many different genetic regions that have been associated with the development of cardiomyopathy. An equal number of genetic regions have been associated with muscular dystrophy and there is overlap because some of the identical genes, when mutated, produce both cardiomyopathy and muscular dystrophy. We are working to identify genes and gene mutations associated with cardiomyopathy, arrhythmias and muscular dystrophy. We propose to screen these samples for mutations in genes known to be involved in these disorders.",[406,30,407],"Cardiomyopathy","Muscular Dystrophy",[406,30,407],{"date":410,"type":41},"2025-09-09",{"date":412,"type":4},"1996-09",{"date":414,"type":21},"2030-01",{"name":416,"class":48},"University of Chicago",{"id":418,"slug":4,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":423,"targetDuration":425,"studyType":23,"phases":4,"briefSummary":426,"conditions":427,"keywords":431,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":440,"locationsCount":114},"100446546","NCT05094843","The Cardiac Stress and Electrocardiographic Changes Caused by Lung Cancer Surgery","The Cardiac Stress and Electrocardiographic Changes Caused by Lung Cancer Surgery.","Inclusion Criteria:\n\n* Adult patients scheduled for elective lung cancer surgery\n* Willing to participate in the study\n* Curatively aimed surgery\n* Preoperative decision for mini-invasive surgery\n\nExclusion Criteria:\n\n* Participation in any other clinical trial\n* Previous chronic or paroxysmal atrial fibrillation or atrial flutter\n* Cardiac pacemaker\n* History of cardiac conduction disturbances including bundle branch blocks\n* History of cardiac ablation procedures\n* History of previous surgery in the thoracic area including open heart surgery\n* Preoperatively anticipated need for concomitant thoracic wall resection\n* Preoperatively anticipated need for open surgery",{"count":424,"type":21},100,"3 Weeks","Lung cancer surgery causes significant changes in the small circulation as well as changes in the intrathoracic anatomy. The effects of lung cancer surgery on electrocardiography and the cardiac stress associated with the procedures have not been previously extensively studied. The aim of the present study is to ascertain whether modern mini-invasive lung cancer surgery causes changes in the electrocardiogram, and whether these changes are transitory during short-term follow-up. Furthermore, the study aims to describe whether lung cancer surgery causes significant cardiac stress detectable by intraoperative electrocardiography.",[428,429,30,430],"Lung Cancer","Surgery","Myocardial Ischemia",[432,433,30],"Lung cancer","Electrocardiogram","2025-09-03",{"date":436,"type":41},"2025-09-10",{"date":438,"type":41},"2022-03-01",{"date":392,"type":21},{"name":441,"class":48},"Tampere University Hospital",{"id":443,"slug":4,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":447,"enrollmentInfo":448,"targetDuration":121,"studyType":23,"phases":4,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":114},"100602468","NCT07123896","Arrhythmia Cohort Study","Inclusion Criteria:\n\n* Patients hospitalized for any type of arrhythmia\n\nExclusion Criteria:\n\n* Patients currently participating in interventional clinical trials that may confound data collection or outcome assessment in this study.","90 Years",{"count":350,"type":21},"The goal of this prospective, observational registry study is to evaluate the long-term effectiveness, safety, and impact of different kinds of treatment on the quality of life across diverse arrhythmia subtypes and patient populations in hospitalized adults with cardiac arrhythmias (including atrial fibrillation, atrial flutter, supraventricular tachycardia, and ventricular arrhythmias) undergoing routine clinical care.",[30],"2025-08-12",{"date":453,"type":41},"2025-08-14",{"date":455,"type":21},"2025-08-24",{"date":457,"type":21},"2030-07-24",{"name":84,"class":48},{"id":460,"slug":4,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":11,"sex":17,"minAge":465,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":59,"phases":468,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":4},"100601034","NCT07105241","Virtual Reality in Electrophysiological Procedures and Device Implantation: the VR inEP Trial","VR inEP","Inclusion Criteria:\n\n* ≥16 years of age\n* Planned to undergo an invasive electrophysiological procedure (e.g., catheter ablation or electrophysiological study) or cardiac device implantation (e.g., pacemaker or implantable cardioverter defibrillator).\n* The procedure must be performed under local anesthesia.\n\nExclusion Criteria:\n\n* Patients undergoing procedures using (conscious) sedation\n* Patients who do not speak or understand Dutch\n* History of dementia\n* Severe visual impairment.","16 Years",{"count":467,"type":21},115,[61],"Each year about 37,000 patients undergo a catheter ablation to treat cardiac arrhythmias or have a cardiac device such as a pacemaker or implantable cardioverter defibrillator implanted in the Netherlands. Although the procedures positively impact health related outcomes on the long term, they are often accompanied by periprocedural pain and anxiety on a shorter term. These negative effects can be prevented or treated by pharmacological interventions (e.g. analgesics or benzodiazepines), but side effects of these drugs may compromise patient safety and extend hospital admissions. Distraction using Virtual Reality (VR) may be an attractive non-pharmacological alternative.\n\nIt is the aim of the Virtual Reality in Electrophysiological Procedures and device implantation (VR inEP) trial to study the feasibility and efficacy of VR to decrease experienced pain and anxiety in patients undergoing invasive procedures for arrhythmias and conduction disorders. The study also serves as a stepping stone towards structural implementation of VR into clinical care, by familiarizing care personnel of the cardiac catheterization rooms with the use of VR, its indications and logistics, and identifying potential barriers for structural implementation of VR.\n\nVR inEP is a single-center, open label, randomized controlled trial performed in the catheterization rooms in the Radboudumc. Adult patients undergoing an electrophysiological procedure (e.g., catheter ablation or electrophysiological study) or cardiac device implantation (e.g., pacemaker or implantable cardioverter defibrillator) performed under local anesthesia are eligible for inclusion. Patients consenting to participate are randomized in a 1:1 ratio to the VR intervention or control group, stratified for the indication for the procedure (50% electrophysiological procedures, 50% cardiac device implantations). Patients and their treatment teams are unblinded for the treatment allocation. The primary outcomes are pain perception and anxiety during the procedure as a whole, quantified using the visual analog scale (VAS) for pain and the numeric ranking scale (NRS) for anxiety, 30 minutes after the procedure ends.",[30,471,472,473,474,475],"Cardiac Implantable Electronic Device","Ablation of Arrhythmias","Electrophysiologic Study","Pacemaker","ICD","2025-07-29",{"date":367,"type":41},{"date":479,"type":21},"2025-11-15",{"date":481,"type":21},"2026-07-31",{"name":483,"class":48},"Radboud University Medical Center",{"id":485,"slug":4,"hasResults":11,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":11,"sex":17,"minAge":490,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":492,"conditions":493,"keywords":495,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":114},"100571915","NCT06726460","Validation of the Accuracy of a Novel POCT Dry Electrolyte Analysis System in the Acute Care Setting","Validation of the Accuracy of a Novel POCT Dry Electrolyte Analysis System in the Acute Care Setting: A Cross-Sectional Study","Inclusion Criteria:\n\n* Patients who are scheduled to undergo electrolyte measuring in the emergency department (ED) or emergency intensive care unit (ICU).\n\nExclusion Criteria:\n\n* Patients with a confirmed history of infectious diseases such as hepatitis B, syphilis, HIV\u002FAIDS, etc.\n* Missing residual sample types (serum or whole blood).\n* Patients whose residual blood samples are not tested within the specified time frame after collection.\n* Other patients deemed ineligible by the investigator.","28 Days",{"count":124,"type":21},"The goal of this study is to compare the performance of a novel Point-of-Care Testing (POCT) dry electrolyte analyzer (P1) with the Nova Stat Profile pHOx Ultra Analyzer System (Nova) in an acute care setting. The main questions it aims to answer are:\n\n1. How consistent are the results between P1 and Nova in the emergency setting, including outliers, correlation, linearity, and bias?\n2. Whether P1 can serve as a suitable alternative to Nova in the acute care setting for electrolyte measurement in the emergency environment.\n\nParticipants will be patients in the emergency department who will undergo simultaneous measurement with P1 and Nova during their emergency care to assess the performance of both devices.\n\nAdditionally, the study will investigate electrolyte levels in emergency patients, focusing on the prevalence of abnormal ionized magnesium (iMg2+) levels, the correlation between iMg2+ and total magnesium (tMg), and the clinical significance of iMg2+ measurement.",[494,30,272],"Electrolyte Disorder",[496,497,498,499],"Electrolyte Analyzer","Accuracy","P1","Eaglenos","2025-07-15",{"date":502,"type":41},"2025-07-18",{"date":504,"type":41},"2024-12-17",{"date":506,"type":21},"2025-10-31",{"name":508,"class":48},"Zhujiang Hospital",{"id":510,"slug":4,"hasResults":11,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":515,"targetDuration":4,"studyType":59,"phases":517,"briefSummary":518,"conditions":519,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":114},"100415106","NCT04685317","Safety and Efficacy of the Sentinel Cerebral Protection Device in Atrial Fibrillation Ablation","A Pilot Randomized Study of the Use of The Sentinel Device for Cerebral Protection During Atrial Fibrillation Ablation","Inclusion Criteria:\n\n* Men \u002F women over the age of 18 years undergoing radiofrequency, pulsed field or cryo-balloon ablation for AF in accordance with the current AHA\u002FACC\u002FHRS guideline for management of patients with atrial fibrillation. This includes patients with symptomatic paroxysmal, persistent or long-standing persistent AF not responsive to or intolerant of a Class I or III anti-arrhythmic drug or patients with symptomatic paroxysmal or persistent AF prior to the initiation of a Class I or Class III antiarrhythmic drug). The decision to perform catheter ablation for AF will be made by the treating provider and the patient in accordance with the guidelines noted above. (January et al. J Am Coll Cardiol vol. 64, No. 21, 2014, page e1)\n* Able to provide informed consent.\n* Patients should have acceptable aortic arch anatomy and vessel diameters without significant stenosis as assessed using pre-procedure CT angiogram.\n\nExclusion Criteria:\n\n* Anatomy unsuitable for use of Sentinel device:\n\n  * Right extremity vasculature not suitable due to compromised arterial blood flow.\n  * Brachiocephalic, left carotid or aortic arch not suitable due to excessive tortuosity, significant ectasia, stenosis (\\>70%), dissection or aneurysm.\n* Cerebrovascular accident or transient ischemic attack within six months\n* Carotid disease requiring treatment within six weeks\n* Unable or unwilling to provide informed consent.\n* Pregnant women\n* Known history of dementia.\n* Known hypersensitivity to nickel-titanium.\n* Presence of MRI non-compatible implanted devices including cardiac implantable electronic devices.\n* The presence of left atrial thrombus. All patients routinely undergo transesophageal echocardiogram prior to ablation and \u002F or intra-cardiac echocardiogram at the beginning of the ablation procedure to rule out the presence of left atrial thrombus.\n* Patients with a reversible cause for AF such as hyperthyroidism.",{"count":516,"type":21},48,[61],"The purpose of the study is to see if the Sentinel® Cerebral Protection System may prevent occurrence of stroke during an ablation procedure for atrial fibrillation (AF). The secondary purpose of this study is to study if cognitive function after AF ablation differs between those treated with the Sentinel cerebral protection device and those who do not receive the device.",[30,70],"2025-06-09",{"date":522,"type":41},"2025-06-11",{"date":524,"type":41},"2023-03-07",{"date":526,"type":21},"2026-12",{"name":528,"class":48},"Malini Madhavan",{"id":530,"slug":4,"hasResults":11,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":535,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":538,"conditions":539,"keywords":541,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":114},"100591769","NCT06984731","The Safety and Efficacy of Radiofrequency Ablation After Left Atrial Appendage Occlusion.","Clinical Trial Protocol for Safety and Efficacy of Transcatheter Ablation After Left Atrial Appendicular Occlusion With WATCHMAN FLX","Inclusion Criteria:\n\n1. ≥18 years of age, diagnosed with nonvalvular atrial fibrillation;\n2. Meet the indications for receiving WATCHMAN FLX left atrial appendicular closure and transcatheter atrial fibrillation ablation;\n3. Preoperative imaging evaluation showed that the anatomical structure of the left atrial appendage was suitable for implantation with the WATCHMAN FLX device;\n4. The patient agrees to participate in the study and signs the informed consent.\n\nExclusion Criteria:\n\n1. valvular heart disease or other structural heart disease that causes atrial fibrillation;\n2. left auricular thrombus or acute thrombotic event was found before surgery;\n3. Patients with severe bleeding tendency or recent major bleeding events (such as massive gastrointestinal bleeding, cerebral hemorrhage, etc.);\n4. Patients who are unable to complete postoperative follow-up (such as life expectancy of less than 1 year or poor compliance);\n5. Other serious diseases (such as liver and kidney failure, active infection, etc.) were found in preoperative examination;\n6. Pregnant or lactating women.","80 Years",{"count":537,"type":21},210,"Objective: To evaluate the safety and efficacy of transcatheter atrial fibrillation ablation 1 month after WATCHMAN FLX left atrial appendage closure in patients with nonvalvular atrial fibrillation.",[540,30],"Cardiovascular Diseases",[66,542,543],"Left Atrial Appendage closure with WATCHMAN device","Radiofrequency ablation","2025-05-18",{"date":546,"type":41},"2025-05-22",{"date":548,"type":41},"2025-04-21",{"date":550,"type":21},"2028-06-01",{"name":552,"class":48},"Affiliated Hospital of Nantong University",{"id":554,"slug":4,"hasResults":11,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":560,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":562,"conditions":563,"keywords":570,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":4},"100591796","NCT06985082","This is an Observational Study That Aims to Demonstrate Postoperative Risk Factors in Pediatric Cardiac Surgery","Risk Factors for Postoperative Complications in Pediatric Cardiac Surgery: A Retrospective Observational Study","PEDS-CARE","Inclusion Criteria:\n\n* All patients under 18 years of age who underwent cardiac surgery\n\nExclusion Criteria:\n\n* Patients undergoing non-cardiac thoracic surgeries\n* Patients over 18 years of age\n* Pregnant women will be excluded from the study",{"count":561,"type":21},310,"This retrospective observational study aims to identify risk factors for postoperative complications in children undergoing cardiac surgery at a tertiary hospital in Brazil. By analyzing both electronic and physical medical records, researchers will examine demographic, clinical, surgical, and laboratory data, focusing on variables such as cardiopulmonary bypass (CPB) time, use of vasoactive drugs, and the occurrence of complications such as arrhythmias, acute kidney injury, and infections. Statistical analysis will include both descriptive and inferential methods, with multivariate logistic regression used to identify predictors of adverse outcomes. The study will be conducted between 2025 and 2027 with an estimated budget of R$1,000. Its goal is to inform preventive strategies and optimize perioperative care, ultimately improving patient outcomes and reducing hospital costs.",[30,564,565,566,567,568,569],"Acute Kidney Injuries","Sepsis","Pneumopathy","Thrombosis","Ventricular Asynchrony in Cardiac Surgery Patients","Pediatric Cardiac Surgery",[569,571,572],"Risk Factors Postoperative","Complications Posoperative","2025-05-14",{"date":546,"type":41},{"date":576,"type":21},"2025-05",{"date":578,"type":21},"2025-08",{"name":580,"class":48},"Instituto de Cardiologia do Rio Grande do Sul",{"id":582,"slug":4,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":588,"targetDuration":590,"studyType":23,"phases":4,"briefSummary":591,"conditions":592,"keywords":594,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":606,"locationsCount":317},"100584969","NCT06896266","Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy","Understanding and Characterizing the Genetics of Patients With Arrhythmia-Induced Cardiomyopathy","UNCHAINED-I","Inclusion Criteria:\n\n* Presence of atrial fibrillation or atrial flutter not self-limited.\n* Performance of a cardiac imaging test with systolic function analysis (echocardiogram, magnetic resonance, CT scan) during the clinical course of the arrhythmia, exhibiting a left ventricular ejection fraction (LVEF) \\\u003C50%. In order for the test to be representative, the maximum time between the performance of the imaging test and the rhythm control procedure will be 3 months, in the absence of intervening cardiovascular events that may have caused a variation in LVEF. In the event that the patient had a previously known LVEF \\\u003C50%, the change with respect to this attributable to tachyarrhythmia has to be ≥10%.\n* Signature of informed consent.\n* Ability to understand and accept participation in the study.\n\nExclusion Criteria:\n\n* Refusal of informed consent.\n* Legal or juridical incapacity.\n* Age \\\u003C18 years.\n* Life expectancy less than 1 year.\n* Impossibility of a follow-up of at least 6 months.\n* Presence of a ventricular rate \\>140 beats per minute, limiting the validity of imaging measurements.\n* Presence of known factors causing systolic ventricular dysfunction:\n\n  * Prior cardiomyopathy diagnosis.\n  * Severe mitral or aortic valve disease.\n  * Non-revascularizable ischemic heart disease.\n  * Context of peri-resuscitation cardiopulmonary care.\n  * Abusive alcohol consumption, defined as \\>80 grams of ethanol or \\>7 standard alcoholic beverages per day.\n  * Active treatment with chemotherapeutic agents or radiation therapy to the thorax.\n  * Known infection with Trypanosoma cruzi, Borrellia burgdorferi or other infectious agent causing cardiomyopathy.",{"count":589,"type":21},109,"1 Year","The goal of this observational study is to learn about the genetic insights of arrhythmya-induced cardiomyopathy and its clinical prognosis. The main questions it aims to answer are:\n\nI. Does patients with arrhythmia-induced cardiomyopathy have a greater proportion of genetic mutations compared with other types of cardiomyopathy or general population? II. Have the genetics any prognostic impact in patients with arrhythmia-induced cardiomyopathy?",[30,406,593],"Arrhythmia-induced Cardiomyopathy (AiCM)",[595,596,597,598,599,600],"atrial fibrillation","atrial flutter","heart failure","arrhythmia-induced cardiomyopathy","cardiomyopathy","genetics","2025-05-09",{"date":573,"type":41},{"date":604,"type":41},"2024-12-01",{"date":526,"type":21},{"name":607,"class":48},"Hospital Universitario 12 de Octubre",{"id":609,"slug":4,"hasResults":11,"nctId":610,"briefTitle":611,"officialTitle":611,"acronym":612,"eligibilityCriteria":613,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":614,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":615,"conditions":616,"keywords":621,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":114},"100589414","NCT06954103","Mechanisms And Prognosis of Stroke-Heart Syndrome","MAP-SHS","Inclusion Criteria:\n\n1. Patients admitted within 48 hours of onset, confirmed by CT\u002FMRI as having a stroke (including acute ischemic stroke and hemorrhagic stroke).\n2. Moderate-to-severe stroke with NIHSS ≥ 5.\n\nExclusion Criteria:\n\n1. Previous focal brain injury (such as stroke, brain surgery, traumatic brain injury, etc.).\n2. Brain dysfunction caused by other major neurological disorders than stroke (such as brain tumors, epilepsy, Parkinson's disease, etc.).\n3. Transient ischemic attack (TIA) and subarachnoid hemorrhage (SAH).\n4. History of cardiac diseases (such as coronary heart disease, heart failure, severe arrhythmias, congenital heart disease, cardiac surgery, valvular heart disease, or undiagnosed significant cardiac symptoms).\n5. Concomitant systemic diseases such as renal failure (eGFR \\\u003C 30), autoimmune disorders, severe infections, etc.\n6. History of dementia, depression, or other psychiatric disorders.\n7. Poor compliance and inability to cooperate with follow-up.",{"count":58,"type":21},"The incidence of stroke-heart syndrome following acute stroke, which encompasses both acute ischemic stroke and acute intracerebral hemorrhage, is notably high and is strongly associated with increased mortality and poor outcomes in stroke patients. However, the underlying mechanisms remain unclear, and there are currently no effective prevention or treatment strategies. This study aims to elucidate the neuro-humoral mechanisms of stroke-heart syndrome through multimodal imaging and multi-omics blood analysis. Additionally, it seeks to observe the progression of stroke-heart syndrome and its impact on functional outcomes, cognitive abilities, and emotional issues post-stroke. The research is expected to uncover novel blood biomarkers and brain network mechanisms associated with stroke-heart syndrome, providing potential targets and theoretical foundations for pharmacological treatments or physical interventions. Furthermore, it aims to establish a risk early-warning system for major cardiovascular complications post-stroke, enabling early identification, early intervention, and integrated brain-heart management to improve clinical outcomes for stroke patients.",[272,617,27,26,30,618,619,620],"Myocardial Injury","Sudden Cardiac Death","Takotsubo Syndrome","Heart Rate Variability",[622],"Stroke-heart syndrome","2025-04-23",{"date":625,"type":41},"2025-05-01",{"date":627,"type":41},"2025-03-01",{"date":629,"type":21},"2028-04-01",{"name":631,"class":48},"Chensheng Pan",{"id":633,"slug":4,"hasResults":11,"nctId":634,"briefTitle":635,"officialTitle":635,"acronym":636,"eligibilityCriteria":637,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":638,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":640,"conditions":641,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":114},"100523827","NCT06100770","Aveir AR Coverage With Evidence Development (CED) Study","ARRIVE","Inclusion Criteria:\n\n1. Medicare beneficiaries implanted with an Aveir AR leadless pacemaker on or after the study start date (i.e., the date of Aveir AR market approval) will be included in the study.\n\n   OR\n2. Medicare beneficiaries implanted with a full system (e.g. lead and generator) single chamber atrial transvenous pacemaker on or after the study start date\n\nExclusion Criteria:\n\n* None",{"count":639,"type":21},586,"The purpose of this coverage with evidence development (CED) study is to evaluate complications and long-term health outcomes of the single-chamber Aveir Atrial Leadless Pacemaker device (aka Aveir™ AR LP system).",[642,30,153],"Cardiac Pacemaker","2025-04-02",{"date":645,"type":41},"2025-04-04",{"date":647,"type":41},"2024-01-18",{"date":649,"type":21},"2031-01",{"name":651,"class":169},"Abbott Medical Devices",""]